Medicaroid Corporation Sustainability Profile
Medicaroid Corporation, headquartered in Japan, is a pioneering force in the robotics and healthcare industry. Founded in 2015, the company has rapidly established itself as a leader in developing advanced robotic solutions for medical applications, particularly in rehabilitation and assistive technologies. With a focus on enhancing patient care, Medicaroid's core products include innovative robotic systems designed to support physical therapy and improve mobility for individuals with disabilities. Their unique approach combines cutting-edge technology with user-friendly interfaces, setting them apart in a competitive market. Recognised for their commitment to quality and innovation, Medicaroid has achieved significant milestones, including collaborations with leading healthcare institutions. As they continue to expand their operational reach, their dedication to improving healthcare outcomes positions them as a key player in the global medical robotics landscape.
DitchCarbon Score
How does Medicaroid Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Computer Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medicaroid Corporation's score of 62 is higher than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Medicaroid Corporation, headquartered in Japan (JP), currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. However, the company is part of a corporate family that includes Sysmex Corporation, from which it inherits climate-related initiatives and targets. Medicaroid's climate commitments are influenced by its relationship with Sysmex Corporation, which has established science-based targets (SBTi) and participates in the Carbon Disclosure Project (CDP). These initiatives aim to enhance transparency and accountability in carbon emissions management. While specific reduction targets for Medicaroid are not detailed, the overarching goals set by Sysmex Corporation guide its climate strategy. As a current subsidiary of Sysmex, Medicaroid aligns its sustainability efforts with the parent company's initiatives, although no specific reduction achievements or targets have been disclosed at this time. The absence of direct emissions data suggests that Medicaroid is in the early stages of formalising its climate commitments, reflecting a broader industry trend towards increased environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 5,559,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 20,278,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | 00,000,000 | 00,000,000 | 00,000,000 | - | - | - | 000,000,000 | 000,000,000 |
How Carbon Intensive is Medicaroid Corporation's Industry?
How Carbon Intensive is Medicaroid Corporation's Location?
Medicaroid Corporation's Scope 3 Categories Breakdown
Medicaroid Corporation's Scope 3 emissions, which decreased by 4% last year and increased significantly since 2016, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 34% of Scope 3 emissions.
Top Scope 3 Categories
Medicaroid Corporation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Medicaroid Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
